� Kamada (TASE: KMDA), a bio-pharmaceutical company engaged in the development, fabrication and marketing of specialty life-saving therapeutics, announced that it has completed a Phase II Study with Aerosolized Alpha-1 Antitrypsin (AAT), delivered via an optimized eFlow platform nebulizer (PARI Pharma GmbH), in cystic fibrosis (CF). Preliminary results indicate that the product has an excellent condom profile; last data should be available by year-end 2008.
David Tsur, Kamada's CEO expressed satisfaction at the advancement of the company's flagship AAT product for the treatment of cystic fibrosis. "This is a major milestone for Kamada. There is significant potential for the aerosolized version of AAT, which is an innovative approach for handling of chronic inflammatory processes that could potentially prevent degeneration of lung routine. We believe that, pending the successful completion of the trials and registration process, this formulation could considerably improve the timber of liveliness and potentially extend the life expectancy of a wide mountain chain of cystic fibrosis patients."
According to Pnina Strauss, Kamada's Clinical Trials and IP Manager, "We are extremely pleased with this major achievement. Aerosolized giving medication of AAT for cystic fibrosis holds great potential for the treatment of these severely diseased patients. We ar eager to pursue the development of this product and demo the benefit for this patient population as well as other respiratory populations."
About the study
The trial run, which was a double blind, placebo controlled study was performed at the renowned Cystic Fibrosis (CF) Medical Center - Hadassah - Hebrew University Medical Center Mount Scopus in Jerusalem, Israel. The trial aimed at validatory the base hit of the product in CF patients and to assess its potential influence on lung inflammation. The results indicate an excellent safety profile of the product. Further trial details are available at hTTP://www.clinicaltrials.gov.
About Aerosolized AAT
Kamada's Aerosolized AAT, which utilizes an optimized eFlow platform nebuliser (PARI Pharma GmbH), has been designated an Orphan Drug for the handling of CF and Alpha-1 Deficiency, in both Europe and the U.S. This designation grants Kamada various benefits such as enquiry fund support, tax incentives, reduced official fees and seven to twelve days of sole distribution rights, if the company's product is first base on the market. Phase II trials in bronchiectasis are presently ongoing.
About the eFlow� Platform Nebulizer
The eFlow platform atomizer, an electronic, portable nebulizer technology political platform, enables extremely efficient aerosolization of liquid medications via a vibrating, perforated tissue layer. Compared to other spray systems, the eFlow political platform nebulizer derriere produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible amount of prison term. Combined with its silent mode of operation, pocket-sized size (it fits in the palm of your hand), light weight, and battery function, the eFlow platform nebulizer helps quash the core of taking daily inhaled treatments.
About PARI Pharma
PARI Pharma develops aerosol delivery devices and inhaled therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma specializes in treatments for pulmonic and nasal bone administration optimized to advance delivery platforms, such as the eFlow Platform Nebulizer.
About Kamada
Kamada is a world biopharmaceutical fellowship (TASE: KMDA) developing, producing and selling a agate line of specialism life-saving biopharmaceuticals using its proprietary chromatographical purification technologies. Licensed and marketed planetary, several of these peculiarity therapeutics are currently undergoing advanced clinical trials.
http://www.kamada.com
More info
Friday, 5 September 2008
Tuesday, 26 August 2008
The Script continue to top album charts
Irish iII The Script have held on for a arcsecond week to top the album charts in Ireland and the UK with their self-titled debut.
The band have also continued to enjoy success in the UK singles chart where they have stirred up to the Number Two daub with their song 'The Man Who Can't Be Moved'.
They are being held off the Number One spot by Kate Perry, while the single cadaver at Number Three in Ireland.
The highest new ledger entry of the week in the UK charts comes from Damon Albarn's Monkey project, which debuts at five with 'Journey to The West', a "pop opera" performed entirely in Mandarin.
More info
Saturday, 16 August 2008
BioCurex Presents RECAF Results At International Cancer Congress
� BioCurex Inc. (OTCBB:BOCX) announced that the Congress Scientific Committee has recognized its presentation to the ISOBM annual meeting. BioCurex will present results obtained with its ELISA RECAF blood test for cancer at the 2008 assemblage of the International Society of Oncology and Bio-Markers (ISOBM).
The conference volition be held from October 5th to October ninth, in Tokyo, Japan and will land together scientists, clinicians and companies involved in the field of cancer markers.
Dr. Moro stated: "This year's conference is entitled, 'Development of new molecular tumor markers for diagnosing and therapy'. The subject is well chosen and critical for good reason: it reflects the penetrative need, among the scientific community as well as clinicians, for new malignant neoplastic disease markers to be secondhand in genus Cancer diagnosis and therapy. This need arises from the fact that there ar presently very few markers, their boilersuit performance is not very good and they are limited to a few types of cancer. It also reflects on the fact that since AFP and CEA were first described as cancer markers in the early 60's, not many markers get been ascertained. BioCurex has a unique cancer marker in the sense that it combines excellent performance in discriminating patients with cancer from those wHO do non have crab, along with the ability to discover very early stages of two of the most common cancers - breast and prostate gland. RECAF, our marker, too has the potential to be used on a broad spectrum of cancers, which is a fantastic advantage.
At ISOBM 2008 we'll be showing results related to the ELISA format - a type of test that nates be carried out in most research and clinical labs. We expect to elicit substantial interest among scientists to carry out collaborations that will continue to formalise, independently and through legion publications, the very adept performance of the RECAF tests."
To find more about the 2008 ISOBM meeting, go to http://isobm08.umin.jp/index.html
About BioCurex
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a crab marker known as RECAFTM, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations (for farther information on these agreements see hither.)
The malignant neoplastic disease marker RECAFTM has emerged as a potential biomarker that crataegus laevigata be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the near common cancers, including prostate, breast, colorectal, lung and others.
To read more about BioCurex, please shoot the breeze the News section in our web site hypertext transfer protocol://www.biocurex.com.
Note
The Company has not authoritative the outlet of this information in any variant that contravenes the Communication Act and will not be creditworthy for unasked massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this push release, which are non historical facts, are "innovative statements" inside the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are content to change at whatever time, the Company's existent results could differ materially from expected results.
BioCurex
More info
The conference volition be held from October 5th to October ninth, in Tokyo, Japan and will land together scientists, clinicians and companies involved in the field of cancer markers.
Dr. Moro stated: "This year's conference is entitled, 'Development of new molecular tumor markers for diagnosing and therapy'. The subject is well chosen and critical for good reason: it reflects the penetrative need, among the scientific community as well as clinicians, for new malignant neoplastic disease markers to be secondhand in genus Cancer diagnosis and therapy. This need arises from the fact that there ar presently very few markers, their boilersuit performance is not very good and they are limited to a few types of cancer. It also reflects on the fact that since AFP and CEA were first described as cancer markers in the early 60's, not many markers get been ascertained. BioCurex has a unique cancer marker in the sense that it combines excellent performance in discriminating patients with cancer from those wHO do non have crab, along with the ability to discover very early stages of two of the most common cancers - breast and prostate gland. RECAF, our marker, too has the potential to be used on a broad spectrum of cancers, which is a fantastic advantage.
At ISOBM 2008 we'll be showing results related to the ELISA format - a type of test that nates be carried out in most research and clinical labs. We expect to elicit substantial interest among scientists to carry out collaborations that will continue to formalise, independently and through legion publications, the very adept performance of the RECAF tests."
To find more about the 2008 ISOBM meeting, go to http://isobm08.umin.jp/index.html
About BioCurex
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a crab marker known as RECAFTM, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations (for farther information on these agreements see hither.)
The malignant neoplastic disease marker RECAFTM has emerged as a potential biomarker that crataegus laevigata be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the near common cancers, including prostate, breast, colorectal, lung and others.
To read more about BioCurex, please shoot the breeze the News section in our web site hypertext transfer protocol://www.biocurex.com.
Note
The Company has not authoritative the outlet of this information in any variant that contravenes the Communication Act and will not be creditworthy for unasked massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this push release, which are non historical facts, are "innovative statements" inside the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are content to change at whatever time, the Company's existent results could differ materially from expected results.
BioCurex
More info
Thursday, 7 August 2008
Monday, 30 June 2008
Nas Drops N-Word, Delays Album
Hate him now, hear him later.
Controversial rapper Nas has announced that he is moving the release date of his highly anticipated ninth studio album back two weeks, from July 1 to July...
Wednesday, 25 June 2008
Rehearsals and parties set stage for BET Awards
LOS ANGELES —
See Also
The BET Awards buzz has begun.
With the city poised to serve as party central right through Tuesday's awards show, things were already humming around town Sunday.
At downtown's Shrine Auditorium, piles of rolled red carpet stood beside stacks of sound gear while workers bustled outside and Chris Brown, Ciara and Ne-Yo rehearsed inside.
A glitzy gift suite was stocked with watches, sneakers, bejeweled belts and blinged-out iPhone cases that awaited the arrival of A-listers.
Meanwhile, across town in West Hollywood, songwriters and producers gathered at Murano restaurant for the BMI Black Music Month brunch. Rapper Rick Ross, producer Sean Garrett and actress Regina King were among the guests who sipped champagne in honor of the artists behind the music.
Garrett gave credit to Black Entertainment Television for honoring all aspects of entertainment.
"I'm proud of BET," said the producer, who has worked with Britney Spears and Michael Jackson. "BET always gives a sense of where urban is at the moment and how they're trying to grow."
Awards-related festivities were set to continue Sunday night with a party in honor of Lil Wayne and Usher and a dinner celebrating Nelly. More events were scheduled for Monday, including a private dinner hosted by BET chief Debra Lee that was to feature a performance by Jill Scott.
The BET Awards will be broadcast live Tuesday from the Shrine at 8 p.m. EDT.
---
On the Net:
BET Awards: http://www.bet.com/specials/betawards08
See Also
Monday, 16 June 2008
Sigur Ros books quick US tour ahead of new album
Atmospheric alt-rockers Sigur Ros [ tickets ] have lined up a few US dates this month behind the forthcoming release of the band's latest studio effort.The Icelandic group, which finished a brief run of Mexican dates last week, has plotted the shows around its June 14 appearance at the Bonnaroo Festival in Manchester, TN. The mini-run will kick off tomorrow (6/11) in Omaha City, NE. Details are below.The band also has a full schedule of European dates laid out over the summer, complete details for which are posted at the Sigur Ros website.Due in stores June 23, "Med Sud i Eyrum Vid Spilum Endalaust" (English translation: "With a Buzz in Our Ears We Play Endlessly") is the band's fifth studio album, and follows 2005's "Takk...," which was certified gold in the UK and sold more than 30,000 copies in the US during its first week in stores.Despite the unwieldy title, the disc is the group's first to feature a song performed in English ("All Alright.") The album was co-produced by the band with veteran producer Flood (U2, Smashing Pumpkins) and recorded in New York City; London; the band's hometown of Reykjavik, Iceland; and Havana, Cuba.The album's track "Ara Batur," described in a press release as the "largest musical undertaking in the band's career," was recorded live in one take and features the London Sinfonietta and the London Oratory Boy's Choir, making for a total of 90 performers playing at the same time.Last year, the group released "Hvarf-Heim," a 2-CD compilation album containing studio versions of previously unreleased songs, and the live DVD "Heima," which documents the group's 2006 tour of Iceland.
Subscribe to:
Posts (Atom)